New drug combo trial aims to hold back deadly pancreatic cancer
NCT ID NCT05494697
Summary
This study is testing if adding an investigational drug called Ampligen to standard cancer care helps people with locally advanced pancreatic cancer live longer without their cancer getting worse. It will compare the combination to standard care alone in about 90 people who have already completed initial chemotherapy. The main goal is to see if the combination delays cancer progression more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.